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The transcription factor retinoid-related orphan receptor gamma t (RORgt) has emerged as an exciting target
for inflammatory diseases. Xiao et al. (2014) show that a new class of RORgt antagonists can inhibit the
inflammatory function of T helper 17 cells without altering RORgt occupancy on its target genes.The discovery of pathogenic T helper 17
(Th17) cells nearly a decade ago (Ivanov
et al., 2006) has led to the development
of targeting strategies to inhibit inflam-
matory T cell activities for the treatment
of autoimmune disorders. At the core
of these therapeutic approaches is anti-
body-mediated neutralization of inter-
leukin-23 (IL-23) and IL-17, which is
showingencouraging results for treatment
of psoriasis, multiple sclerosis, Crohn’s
disease, and ankylosing spondylitis (Patel
et al., 2013, Sandborn et al., 2012). These
clinical proof-of-concept studies under-
score the advantage and effectiveness
of suppressing retinoid-related orphan
receptor gamma t (RORgt)+IL-23R+ Th17
cells. Additional approaches include (1)
blockade of IL-23R signaling through the
suppression of JAK2- and TYK2-depen-
dent STAT3 activation and (2) direct inhi-
bition of RORgt—the nuclear hormone
receptor (NHR) transcription factor that
controls Th17 cell development and func-
tion. In the current issue of Immunity, Xiao
et al. (2014) describe the screening and
validation of small-molecule inhibitors
of RORg. What distinguishes this study
from others is the combined use of
a large-scale pharmaceutical discovery
platform with innovative genome-wide
analysis of RORgt target genes in Th17
cells. Aside from its potential clinical
value, the advantage of small-molecule
inhibitors of a NHR transcription factor is
the opportunity to dissect the molecular
mechanisms of RORgt regulation and the
RORgt-dependent transcriptional land-
scape not only in Th17 cells but also in
other RORgt-expressing cell types.
Screening through a library of (2
million) small-molecule compounds, Xiao
et al. (2014) identified TMP778, TMP920,
and GSK805, which bound to and in-
hibited the RORg ligand-binding domain
(LBD) from interacting with cofactorpeptide steroid receptor coactivator 1
(SRC-1) in a fluorescence resonance
energy transfer assay. These compounds
were highly selective for RORg, and
importantly, the inhibitory effect of the
compounds on RORgt was confirmed
through the suppression of effector cyto-
kines from Th17 cells. The compounds
also inhibited two different RORgt-depen-
dent models of autoimmunity in vivo:
experimental autoimmune encephalomy-
elitis and imiquimod-induced skin inflam-
mation (Skepner et al., 2014). Treatment
not only delayed the onset of disease
but also reduced the severity of disease
progression in both models. These results
support the identification of compounds
that not only bind to RORgt but also effec-
tively inhibit RORgt function both in vitro
and in vivo.
RORgt belongs to a family of NHR
transcriptional factors that are composed
of protein structures with a separate
DNA-binding domain (DBD) and LBD.
The DBD imparts gene-targeting speci-
ficity, whereas the LBD serves as control
switches for transcription regulatory func-
tions (Huh and Littman, 2012). Over the
past few years, the search for RORgt
inhibitors has yielded molecules that
engage the LBD, induce conformational
changes, and prevent recruitment of co-
activators (e.g., SRCs). Examples include
diverse chemical structural classes of
compounds, including digoxin, SR1001,
and ursolic acid (Huh et al., 2011, Solt
et al., 2011, Xu et al., 2011). Digoxin and
SR1001 bind the LBD of RORg and inhibit
the recruitment of coactivator SRCs
by disrupting helix H12 of the RORgt
ligand-binding pocket. Ursolic acid also
interrupts RORg LBD interaction with
SRC-1, and all of the compounds effec-
tively inhibit expression of genes that
are preferentially expressed in Th17 cells.
However, until now, the direct effects ofImmunityRORgt inhibitors on RORgt-dependent
transcription programs have not been
analyzed in detail.
By taking the innovative approach
of pairing chromatin immunoprecipita-
tion sequencing (ChIP-seq) and RNA
sequencing (RNA-seq) data, Xiao et al.
(2014) were able to gain broad insights
into the direct transcriptional effects
of the RORgt inhibitors on the basis
of changes in RORgt occupancy on its
target genes, as well as global transcrip-
tional modulations. As expected, many
of the genes that were suppressed after
treatment with the inhibitors were Th17-
cell-specific genes, such as Il17a and
Il23r, confirming the strong inhibition of
Th17 cell differentiation and IL-17 produc-
tion. However, similar to Rorc/ cells,
RORgt-inhibited cells also led to the
induction of signature genes from other
CD4+ T helper cell lineages, such as Il4
and Tbx21. As observed for many other
transcriptional regulators, RORgt func-
tions as both an activator and a repressor
of a wide range of target genes, and
the effect of the inhibitors reveals an
important function of RORgt in positively
regulating the transcriptional signature
of Th17 cells while suppressing those of
other T helper cell lineages.
How do the inhibitors suppress the ac-
tivity of RORgt? Is it simply by interrupting
RORgt from binding its target genes, or
is it by disrupting RORgt interaction with
other transcription factors or coactiva-
tors? The answer proved to be both, but
interestingly, it was specific to the com-
pound itself. Xiao et al. (2014) compared
compound-induced changes in RORgt
gene occupancy by using genome-wide
ChIP-seq, and surprisingly, the data re-
vealed remarkable insights for themecha-
nism of action between the different
RORgt inhibitors (Figure 1). Whereas
compound TMP920 clearly abrogated40, April 17, 2014 ª2014 Elsevier Inc. 451
Figure 1. Mechanisms of Functional RORgt Inhibition by Small-Molecule Inhibitors
(Top) RORgt, IRF4, BATF, and STAT3 occupancy on Il17a and Gata3 in Th17 cells. RORgt and coregula-
tory transcription factors induce IL17a transcription, whereas Gata3 expression is inhibited.
(Center) Treatment with TMP920 during Th17 cell polarization inhibits RORgt occupancy on Il17a, and
IL17a transcription is inhibited. RORgt occupancy on Gata3 is not affected by treatment with TMP920.
(Bottom) In contrast to treatment with TMP920, treatment with TMP778 preserves RORgt occupancy on
IL17a; however, IL17a transcription is inhibited. TMP778 bound to RORgt allows occupancy at additional
target genes, including Gata3. Whether the suppression of Il17a is through the inhibition of RORgt
interaction with coregulatory proteins or through indirect suppression from Gata3 transactivation and
GATA3-induced proteins such as IL-4 and downstream STAT6 signaling remains to be determined.
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RORg binding activities were preserved
when cells were treated with TMP778
or GSK805. An unanticipated effect of
TMP778 or GSK805 was that these com-
pounds appeared to stabilize RORgt
occupancy in certain genomic loci, and
interestingly, treatment with either com-
pound led to RORgt occupancy in new
binding sites normally not seen in Th17
cells. A region of particular interest was
the binding of RORgt to Gata3 when cells
were treated with TMP778 or GSK805.
These compounds induced an increase
in both Gata3 mRNA and protein expres-
sion. In light of this interesting observa-
tion, additional unanswered questions
arise. How do the compounds alter
RORgt DNA binding, and do the addi-
tional RORgt occupancy sites contribute
to the suppressed Th17 cell phenotype?
It is possible that transactivation of452 Immunity 40, April 17, 2014 ª2014 ElsevGata3 by RORgt participates in the inhibi-
tion of Th17 cell signature genes in cells
treated with TMP778 or GSK805, perhaps
through the induction of GATA3 target
genes (Figure 1). Additional studies
analyzing the effect of the compounds
on RORgt interaction with coactivators
and corepressors through a proteomics
approach might further shed valuable
insights into the molecular mechanisms
of RORgt inhibition.
The strategic value of analyzing the
transcriptional profile in conjunction with
RORgt target-gene occupancy is the
unprecedented glimpse into the poten-
tial diversity in the inhibitory mechanisms
of RORg small-molecule antagonists.
Although the global downstream effects
after treatment with a range of com-
pounds might appear similar, the data
presented clearly show that the actual
molecular mechanism can be quiteier Inc.diverse. The data highlight two impor-
tant points: (1) combining an unbiased
genome-wide transcription factor binding
assay via ChIP-seq with global transcrip-
tional modulation analysis demonstrates
a profound alteration of the Th17 cell tran-
scriptional signature after treatment with
RORg antagonists and (2) RORgt might
lead to ‘‘fine tuning’’ of CD4+ T helper
cell fate by supporting the Th17 cell cir-
cuitry while repressing the ‘‘default’’ Th2
cell fate. Treatment with the compounds
effectively demonstrates the dual nature
of RORgt as a transcriptional activator
and repressor of genes that destabilize
Th17 cells. Studies understanding the
interaction between RORgt and coacti-
vators or corepressors and how this asso-
ciation regulates Th17 cell fate will be an
exciting future research avenue.REFERENCES
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